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abnormalities) applied to patients ≤55 years, and that these
factors retained their independent impact in this subgroup of
patients individually stratified according to age, gender and
Rai stage. In the study by Parikh et al., the authors found that
patients in Rai 0 stage with mutated IGHV genes or patients
in Rai stage 0 with either 13q deletion or normal FISH had an
overall survival comparable to that of the sex- and age-
matched population. Indeed, the overall survival was signifi-
cantly longer in young patients with no adverse factors
(median overall survival not reached), one adverse factor (13
years), or two adverse factors (7.7 years). Bearing in mind
that most young CLL patients die of their disease7,17 and that
their relative survival is definitely shortened, there is clear
room for improvement in the therapeutic options for these
patients. 
In summary, Parikh et al.16 reported the clinical and biolog-
ical characteristics of the largest series of CLL patients ≤55
years old at diagnosis published so far and included for the
first time the analysis of the biomarkers identified in the last
15 years. They showed that patients ≤55 years with CLL fre-
quently had high-risk disease resulting in a shorter time to
first treatment and a significantly reduced overall survival
compared to that of a sex- and age-matched population. A
comparison with historical series did not show a significant
improvement in overall survival through the decades for this
subgroup of patients. The authors, nevertheless, identified a
subgroup of patients ≤55 years with good risk CLL who had
an overall survival comparable to that of a sex- and age-
matched population in the 10 years following diagnosis. A
longer follow-up is required to confirm this comparable over-
all survival in the long-term because of the long life expectan-
cy of individuals of this age. Furthermore, the retrospective
nature of the study resulting in variable availability of bio-
marker data, heterogeneity in the treatment given to patients,
and lack of information on recently described recurrent
mutations in CLL necessitates additional studies that could
improve the management of patients diagnosed with CLL at
a young age.
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In this issue of Haematologica Scheid et al. report on aprospective multicenter clinical trial conducted by theGMMG and Hovon groups which evaluated the prog- nostic role of renal impairment in patients with multiplemyeloma treated with bortezomib before and after autolo-gous stem cell transplantation.1
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Patients were randomized to receive induction (3 cycles)
with either VAD (vincristine, adriamycin, dexamethasone)
or PAD (bortezomid, adriamycin, dexamethasone) fol-
lowed by autologous transplantation and maintenance ther-
apy with either thalidomide (VAD-arm) or bortezomib (1.3
mg/m2 every 2 weeks) (PAD arm). Eighty-one of the 827
patients (10%) included in the trial had a creatinine level ≥2
mg/dL and represent the focus of the study. In this subset of
patients those treated with bortezomib (PAD arm) had a
significantly higher progression-free survival rate than those
in the VAD arm (3-year progression-free survival 48% versus
16%, respectively). The same held true for overall survival
(3-year overall survival 74% versus 34%, respectively).
Moreover, in bortezomib-treated patients the outcome was
similar for those with creatinine ≥2 mg/dL or <2 mg/dL.
These results indicate that this bortezomib-based approach
not only improves outcome but also overcomes the adverse
prognostic influence of renal impairment.
Approximately 20% of patients with multiple myeloma
present with a creatinine concentration ≥2 mg/dL, a factor
associated with poorer survival as demonstrated in the
Durie and Salmon classification (stage B) and in the
International Staging System (high β2 microglobulin levels
are partially associated with abnormal renal function).2,3
However, these classifications systems were derived from
patients treated with conventional chemotherapy, and it
has been suggested that renal impairment may no longer be
a negative prognostic factor with the use of novel agents,
such as bortezomib, thalidomide and lenalidomide.4,5
Nevertheless, it should be noted that renal impairment is a
frequent exclusion criterion in large randomized trials and
information about these patients, particularly those with
severe impairment (creatinine clearance <30 mL/min) is,
therefore, scanty.
The activity of novel agents in patients with renal impair-
ment has been extensively reviewed in several recent
papers.4,5 Bortezomib can be administered at the full
approved dose because its pharmacokinetics is not affected
by the degree of renal impairment. Similarly, no dose reduc-
tions are required for thalidomide (although clinical data are
limited), while the pharmacokinetics of lenalidomide is
affected by its renal route of excretion and dose adjustments
are recommended for moderate/severe renal impairment.4,5
Bortezomib has produced similar response rates and pro-
gression-free survival in relapsing patients with and with-
out renal impairment (glomerular filtration rate > or ≤50
mL/min), but with a trend to a shorter overall survival in
those with severe/moderate renal impairment.6 A similar
picture was observed in newly diagnosed patients (VISTA
trial).7 As far as lenalidomide is concerned, in the combined
analysis of the multiple myeloma 009/010 phase III studies8
no significant differences in response rates were observed
among patients with no/mild renal impairment versusmod-
erate versus severe renal impairment, but progression-free
survival and overall survival were shorter in the cohorts
with moderate/severe renal impairment.
The present study by Scheid et al.1 focused on a subset of
patients who were candidates for autologous stem cell
transplantation (ASCT), all of whom had a creatinine clear-
ance <50 mL/min (median 26 mL/min), and clearly illustrat-
ed that the presence of baseline renal impairment had a
detrimental effect in the VAD followed by ASCT and
thalidomide maintenance arm, with a 50% reduction in
overall survival compared to that in patients with normal
renal function. By contrast the PAD regimen used in this
trial appeared to abrogate the negative prognostic influence
of renal impairment. One relevant question is whether the
benefit in both progression-free and overall survival
observed in the PAD arm is just due to the effect of induc-
tion treatment or if the maintenance phase with borte-
zomib also plays a relevant role in this subset of patients
with renal impairment. Interestingly, although there was a
trend to a higher renal response rate in the PAD arm than in
the VAD arm after induction, the difference was not statis-
tically significant. This suggests that not only induction but
also maintenance with bortezomib after ASCT may be
important in this high-risk population defined by renal
impairment.
Overall, this prospective study shows that in transplant
candidates with moderate/severe renal impairment a borte-
zomib-based regimen may be a standard of care.
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